Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving biomarkers. The trials were global, involved ...
As the brain ages, dopamine-producing cells and receptors gradually disappear, but surviving cells can ramp up dopamine production to compensate. It’s a kind of biological workaround — and, as ...
Hosted on MSN
Novo Nordisk’s Semaglutide Falls Short In Alzheimer’s Study, Showing No Slowing Of Disease
Alzheimer’s patients have received discouraging news after the release of results from a major study. Novo Nordisk confirmed that its Alzheimer’s treatment did not show a “statistically significant” ...
New Scientist on MSN
Inflammation might cause Alzheimer's – here's how to reduce it
Persistent inflammation in the gut, lungs and skin might lead to Alzheimer's disease, but lifestyle choices - from getting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results